2. Peripheral blood draw to evaluate HER2 specific immunity and T -cell memory (100 mls blood). 3. A repeat FDG -PET scan will be perform ed to evaluate inflammatory changes in draining lymph nodes. E. Six months after Booster Vaccination #2 1. Peripheral blood draws to evaluate HER2- specific immunity (by ELISPOT) and T -cell memory (210 mls blood). F. Long Term Follow -up A request for records will be sent to the patient’s primary oncologist twice yearly from the last booster vaccine for a total of 5 years. This information will be put in the study chart which is kept in a locked filing cabinet in a secured building. Study charts are kept for 30 years after the close of the study per University of Washington policy. Information requested will include: a. Most recent laboratory evaluation (CBC, CMP) 6304p Protocol 118 04/06/2016 14 b. Patient’s disease free and overall survival status c. Recent clinical notes which includes history, imaging reports, and physical exam notes Notes will be reviewed by study team for vaccine toxicity and followed up with the patient’s primary physician if indicated. We will look for possible autoimmune symptoms (e.g. unexplained rash, dry eyes, unexplained diarrhea) within the above collected records. 7. EVALUATION AND MANAGEMENT OF TOXICITY Patients must be off all immunosuppressive treatments such as chemotherapy or systemic steroid therapy a minimum of 28 days prior to each booster vaccination. Evalu ation for toxicity will include a physical examination and laboratory evaluation as described in Section 5 (Plan of Treatment.).